The
epilepsy-related risk factors for
vitamin D deficiency, particularly the use of
enzyme-inducing
antiepileptic drugs (EIAEDs), and how to treat
vitamin D deficiency in patients with
epilepsy remain unclear. Our aims were to explore risk factors and the influence of EAIEDs in
vitamin D status and to determine the efficacy of a daily dose of oral
cholecalciferol (
vitamin D3) in epileptic patients with
vitamin D deficiency. Clinical data were collected and
25-hydroxyvitamin D (25(
OH)D) serum levels were measured. All patients with
vitamin D deficiency (25(
OH)D ≤20 ng/mL) or insufficiency (25(
OH)D from 21-29 ng/mL) were treated with 6,670 IU/day
cholecalciferol for eight weeks and 25(
OH)D was then remeasured. Descriptive and inferential statistics were employed. A total of 92 patients (44.6% males), with mean age of 41.0±14.8 years, were included. Measurements of 25(
OH)D revealed that 79.3% patients had abnormal levels: 56.5% were
vitamin D deficient and 22.8% were
vitamin D insufficient. The statistically significant risk factors for
vitamin D deficiency identified were: number of AEDs, treatment with EIAEDs, low sun exposure, high body mass index (BMI) and a high frequency of epileptic
seizures.
After treatment, 25(
OH)D mean level increased by 98.99% (regardless of EIAED use or being
overweight). In our sample, more than half of the adults with
epilepsy showed 25(
OH)D deficiency. Patients on EIAEDs had lower 25(
OH)D levels. A daily dose of 6,670 IU
cholecalciferol successfully led to the correction of 25(
OH)D levels. A higher dose in obese patients or in patients taking EIAEDs may not be warranted and this should be considered in future guidelines for routine
vitamin D deficiency treatment.